Azithromycin treatment failure and macrolide resistance in Mycoplasma genitalium infections in Sofia, Bulgaria

Folia Med (Plovdiv). 2022 Jun 30;64(3):422-429. doi: 10.3897/folmed.64.e63624.

Abstract

Mycoplasmagenitalium is an established cause of sexually transmitted infections in men and women. Current guidelines recommend azithromycin and moxifloxacin as first- and second-line treatment, respectively. However, azithromycin treatment failure has been increasingly reported. The aim of this study was to determine the efficacy of azithromycin and alternative antibiotic regimens in a prospective cohort of M.genitalium-positive patients, and macrolide resistance mutations associated with azithromycin failure.

Keywords: antimicrobial resistance azithromycin failure Bulgaria Mycoplasma genitalium.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use
  • Bulgaria
  • Drug Resistance, Bacterial / genetics
  • Female
  • Humans
  • Macrolides / pharmacology
  • Macrolides / therapeutic use
  • Male
  • Mycoplasma Infections* / drug therapy
  • Mycoplasma genitalium* / genetics
  • Prospective Studies
  • Treatment Failure

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • Azithromycin